Docetaxel, vinorelbine and zoledronic acid as first-line treatment in patients with hormone-refractory prostate cancer

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [1] Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: A phase II study
    Di Lorenzo, Giuseppe
    Autorino, Riccardo
    Perdona, Sisto
    De Laurentiis, Michele
    D'Armiento, Massimo
    Cancello, Giuseppe
    Mirone, Vincenzo
    Imbimbo, Ciro
    Longo, Nicola
    Altieri, Vincenzo
    Tortora, Gianpaolo
    Figg, William D.
    De Placido, Sabino
    EUROPEAN UROLOGY, 2007, 52 (04) : 1020 - 1027
  • [2] Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer
    Vordos, D
    Paule, B
    Vacherot, F
    Allory, Y
    Salomon, L
    Hoznek, A
    Yiou, R
    Chopin, D
    Abbou, CC
    de la Taille, A
    BJU INTERNATIONAL, 2004, 94 (04) : 524 - 527
  • [3] Vinorelbine plus prednisone versus docetaxel plus prednisone as first-line treatment in metastatic hormone-refractory prostate cancer
    Halim, Inas Ibraheim Abdel
    El Sadda, Wael M.
    Farouk, Fatma
    El Sherbeiny, Esam
    El Ashry, Mohamed S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Response to vinorelbine (VNB) as first-line chemotherapy in elderly patients with hormone-refractory prostate cancer (HRPC)
    Cervera Grau, J., Sr.
    Esquerdo Galiana, G.
    Romero Nieto, M.
    Macia Escalante, S.
    Juarez Marroqui, A.
    Llorca Ferrandiz, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Weekly Administration of Docetaxel and Epirubicin as First-Line Treatment for Hormone-Refractory Prostate Carcinoma
    Neri, B.
    Molinara, E.
    Pantaleo, P.
    Rangan, S.
    Crisci, A.
    Della Melina, A.
    Raugei, A.
    Villari, D.
    Nicita, G.
    ONCOLOGY RESEARCH, 2009, 17 (11-12) : 565 - 570
  • [6] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    Investigational New Drugs, 2008, 26 : 75 - 79
  • [7] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Kattan, Joseph G.
    Farhat, Fady S.
    Chahine, Georges Y.
    Nasr, Fady L.
    Moukadem, Walid T.
    Younes, Fariha C.
    Yazbeck, Nadine J.
    Ghosn, Marwan G.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 75 - 79
  • [8] Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients
    Gianfilippo Bertelli
    Abdelhamid Heouaine
    Giuseppe Arena
    Ambrogio Botto
    Ornella Garrone
    Ida Colantonio
    Marcella Occelli
    Elena Fea
    Silvia Giubergia
    Marco Merlano
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 46 - 51
  • [9] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Goodin, S
    Rao, KV
    Kane, M
    Dave, N
    Capanna, T
    Doyle-Lindrud, S
    Engle, E
    Jin, LX
    Todd, M
    DiPaola, RS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) : 199 - 204
  • [10] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Susan Goodin
    Kamakshi V. Rao
    Michael Kane
    Nisha Dave
    Terry Capanna
    Susan Doyle-Lindrud
    Elizabeth Engle
    Lixian Jin
    Mary Todd
    Robert S. DiPaola
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 199 - 204
12345